{"log_id": 6636576118129570683, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.000389, "average": 0.994838, "min": 0.869843}, "location": {"width": 899, "top": 64, "height": 47, "left": 129}, "words": "对这些研究进行非劣效假设检验。低限高于-15%满足帕洛诺司琼和对照药物间的非劣效假设"}, {"probability": {"variance": 4e-05, "average": 0.995848, "min": 0.97224}, "location": {"width": 875, "top": 108, "height": 46, "left": 156}, "words": "研究表明,帕洛诺司琼可有效预防初次和重复中度致吐化疗后120hr(5天)的恶心、呕吐"}, {"probability": {"variance": 1e-06, "average": 0.999102, "min": 0.997236}, "location": {"width": 122, "top": 169, "height": 27, "left": 120}, "words": "【药理毒理】"}, {"probability": {"variance": 1e-05, "average": 0.996261, "min": 0.993032}, "location": {"width": 92, "top": 215, "height": 28, "left": 158}, "words": "药理作用"}, {"probability": {"variance": 0.001234, "average": 0.989273, "min": 0.805748}, "location": {"width": 874, "top": 242, "height": 49, "left": 158}, "words": "帕洛诺司琼为亲和力较强的5HT3受体选择性拮抗剂,对其它受体无亲和力或亲和力较低"}, {"probability": {"variance": 0, "average": 0.935949, "min": 0.935949}, "location": {"width": 25, "top": 272, "height": 25, "left": 1144}, "words": "药"}, {"probability": {"variance": 0.002351, "average": 0.986157, "min": 0.703323}, "location": {"width": 938, "top": 288, "height": 50, "left": 115}, "words": "5-HT3受体位于延髓最后区的催吐化疗感受区中央和周围的迷走神经末梢。化疗药物通过刺激小肠"}, {"probability": {"variance": 0.049575, "average": 0.681468, "min": 0.458813}, "location": {"width": 36, "top": 313, "height": 28, "left": 1141}, "words": "北冫"}, {"probability": {"variance": 0.002377, "average": 0.982434, "min": 0.777291}, "location": {"width": 736, "top": 337, "height": 46, "left": 115}, "words": "嗜铬细胞释放5-HT,5-HT再激活迷走传入神经的5-HT3受体,产生呕吐反射"}, {"probability": {"variance": 0, "average": 0.999263, "min": 0.998408}, "location": {"width": 89, "top": 397, "height": 26, "left": 162}, "words": "毒理研究"}, {"probability": {"variance": 0, "average": 0.99986, "min": 0.999785}, "location": {"width": 73, "top": 442, "height": 28, "left": 160}, "words": "致癌性"}, {"probability": {"variance": 0.000631, "average": 0.992539, "min": 0.830435}, "location": {"width": 876, "top": 468, "height": 48, "left": 168}, "words": "D-1小鼠的104周的致癌性研究中,动物经口给予10、30和60mg/kg/d的帕洛诺司琼治疗"}, {"probability": {"variance": 0.005352, "average": 0.983008, "min": 0.513937}, "location": {"width": 939, "top": 512, "height": 49, "left": 118}, "words": "结果显示,帕洛诺司琼无致癌性。最高试验剂量产生的帕洛诺司的系统暴露量(血浆AUC)为人"}, {"probability": {"variance": 0.015204, "average": 0.925464, "min": 0.380124}, "location": {"width": 938, "top": 553, "height": 57, "left": 118}, "words": "类推荐静脉给予0.25mg帕洛诺司琼后暴露量(AC=9815029倍。在SD大鼠104"}, {"probability": {"variance": 0.020681, "average": 0.937284, "min": 0.412387}, "location": {"width": 954, "top": 598, "height": 56, "left": 121}, "words": "周的致癌性研究中,雄性大鼠和雌性大鼠分别经口给予360gkg、45、90mg/kg/d"}, {"probability": {"variance": 0.020567, "average": 0.944257, "min": 0.366934}, "location": {"width": 936, "top": 648, "height": 46, "left": 124}, "words": "的帕洛诺司琼,最高给药剂量产生的帕洛诺司琼系统暴露量形浆C)为人类推荐给药剂量暴露"}, {"probability": {"variance": 0, "average": 0.745899, "min": 0.745899}, "location": {"width": 24, "top": 680, "height": 19, "left": 719}, "words": "x"}, {"probability": {"variance": 0.001897, "average": 0.987403, "min": 0.745331}, "location": {"width": 943, "top": 692, "height": 48, "left": 121}, "words": "量的137-308倍。使用帕洛诺司琼导致雄性大鼠中良性肾上腺嗜铬细胞瘤和良恶性混合的嗜铬细"}, {"probability": {"variance": 1e-05, "average": 0.998572, "min": 0.980247}, "location": {"width": 939, "top": 735, "height": 49, "left": 123}, "words": "胞瘤发病率上升,胰腺胰岛细胞腺瘤、混合性腺瘤和肉瘤以及垂体瘤的发病率上升,而在雌性大"}, {"probability": {"variance": 0.004038, "average": 0.988862, "min": 0.577426}, "location": {"width": 939, "top": 780, "height": 48, "left": 125}, "words": "鼠中,则会导致肝细胞腺瘤和肉瘤的发生,甲状腺C-细胞腺瘤、混合性腺瘤以及肉瘤的发病率上"}, {"probability": {"variance": 0, "average": 0.999763, "min": 0.999763}, "location": {"width": 26, "top": 844, "height": 27, "left": 125}, "words": "升"}, {"probability": {"variance": 0, "average": 0.999617, "min": 0.999199}, "location": {"width": 93, "top": 885, "height": 27, "left": 170}, "words": "致突变性"}, {"probability": {"variance": 0.000316, "average": 0.993648, "min": 0.881463}, "location": {"width": 894, "top": 912, "height": 46, "left": 169}, "words": "细菌Ames试验、中国仓鼠卵巢细胞致突变试验、体外肝细胞无序DNA合成(UDS)试验或小"}, {"probability": {"variance": 7.4e-05, "average": 0.997403, "min": 0.943358}, "location": {"width": 939, "top": 959, "height": 42, "left": 127}, "words": "鼠的微核试验表明,帕洛诺司琼无致突变毒性。但是,帕洛诺司琼对中国仓鼠卵巢细胞染色体有"}, {"probability": {"variance": 2e-06, "average": 0.998859, "min": 0.996612}, "location": {"width": 93, "top": 1016, "height": 28, "left": 127}, "words": "畸变作用"}, {"probability": {"variance": 1e-06, "average": 0.999176, "min": 0.997938}, "location": {"width": 93, "top": 1059, "height": 28, "left": 172}, "words": "生殖毒性"}, {"probability": {"variance": 0.000121, "average": 0.993866, "min": 0.951454}, "location": {"width": 880, "top": 1090, "height": 45, "left": 172}, "words": "大鼠口服给药剂量为60mg/kg(根据体表面积计算,约为人推荐静脉注射剂量的1894倍)时"}, {"probability": {"variance": 0.000159, "average": 0.994002, "min": 0.946225}, "location": {"width": 385, "top": 1143, "height": 38, "left": 127}, "words": "对雌雄大鼠的生育力和生殖力均无影响"}, {"probability": {"variance": 9e-06, "average": 0.996137, "min": 0.990666}, "location": {"width": 144, "top": 1193, "height": 30, "left": 136}, "words": "【药代动力学】"}, {"probability": {"variance": 1.6e-05, "average": 0.997399, "min": 0.986018}, "location": {"width": 273, "top": 1234, "height": 35, "left": 176}, "words": "以下来自国外临床研究文献"}, {"probability": {"variance": 3e-06, "average": 0.998725, "min": 0.992137}, "location": {"width": 895, "top": 1270, "height": 42, "left": 174}, "words": "健康志愿者和癌症患者分别静脉给予帕洛诺司琼后,随着药物在体内缓慢消除,血药浓度开"}, {"probability": {"variance": 0.010975, "average": 0.959526, "min": 0.39036}, "location": {"width": 933, "top": 1314, "height": 44, "left": 129}, "words": "始下降。无论是健康志愿者还是癌症患者,平均最大血药浓度(C)和药时曲线下面积(AUC--),"}, {"probability": {"variance": 0.002677, "average": 0.986964, "min": 0.660677}, "location": {"width": 934, "top": 1357, "height": 46, "left": 130}, "words": "在0.3-90μg/kg的剂量范围内均呈剂量相关性。六名癌症患者单剂量静脉给予帕洛诺司琼3μ"}, {"probability": {"variance": 0.002284, "average": 0.979716, "min": 0.722682}, "location": {"width": 908, "top": 1403, "height": 43, "left": 132}, "words": "g/kg(或0.21mg/70kg),其最大血药浓度为5.6±5.5ng/ml,平均AUC为35.8±20.9ng·hr/ml"}, {"probability": {"variance": 0.000131, "average": 0.995558, "min": 0.924851}, "location": {"width": 889, "top": 1447, "height": 43, "left": 178}, "words": "11例癌症患者,静脉给予帕洛诺司琼0.25mg,隔天一次,连续3次,1d~5d血药浓度平均"}, {"probability": {"variance": 0.002464, "average": 0.989571, "min": 0.643065}, "location": {"width": 936, "top": 1492, "height": 45, "left": 133}, "words": "增加42±34%。12例健康志愿者,静脉给予帕洛诺司琼0.25mg,每天一次,连续3天,1d~3d血"}, {"probability": {"variance": 0.000338, "average": 0.991024, "min": 0.939057}, "location": {"width": 260, "top": 1550, "height": 28, "left": 135}, "words": "药浓度平均增加110±45%"}], "language": 3}